Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 5Recruiting 4Active not recruiting 4Terminated 3Withdrawn 1Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Pancreatic Neoplasms 1

Interventions

Gemcitabine 5Specimen Handling 2Biopsy 2130-nm albumin-bound paclitaxel 2zimberelimab 1sotigalimab 1poly(I).poly(c12,U) 1palbociclib 1olaparib 1gedatolisib 1durvalumab 1Tomography, Optical Coherence 1Taxes 1Self Expandable Metallic Stents 1S 1 (combination) 1NUC-1031 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1IFL protocol 1Extracorporeal Shockwave Therapy 1Erlotinib Hydrochloride 1Disulfides 1Carnitine 1Calcitriol 1CA-4948 1Albumin-Bound Paclitaxel 1ABTL0812 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Pancreatic Neoplasms × olaparib × Clear all
NCT05411094 2026-05-29

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Suspended
18 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡